Zepbound
Tirzepatide
Zepbound (tirzepatide) is a novel, once-weekly injectable dual agonist that activates GIP and GLP-1 receptors, providing synergistic effects on appetite control and glucose metabolism. Approved for chronic weight management in adults with obesity or overweight and at least one comorbidity, Zepbound has demonstrated unprecedented weight loss results in clinical trials, often approaching surgical outcomes. By targeting two hormone pathways simultaneously, it enhances satiety, slows gastric emptying, and improves metabolic health. Used with a reduced-calorie diet and increased physical activity, Zepbound represents a new generation of obesity medications with promising efficacy across a broad range of patients.
- Manufacturer: Eli Lilly
- Primary Use: Chronic weight management
- Form: Injectable
Common Side Effects
The most common side effects of Zepbound may include:
- Nausea, Diarrhea, Decreased appetite, Vomiting, Constipation
This is not a complete list. Always consult with your healthcare provider about potential side effects.
Medical Disclaimer
The information provided for Zepbound is for informational purposes only and is not a substitute for professional medical advice. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or treatment. Read our full disclaimer.